Steroids: deflazacort & prednisone
StandardEmflaza approved Feb 9, 2017 · ages 2 and older
Daily steroids slow the loss of muscle strength. Long-term use can weaken bones and slow growth. Steroids must never be stopped suddenly.
There is no cure for Duchenne muscular dystrophy (DMD). It is caused by changes in the DMD gene that leave muscles without dystrophin, a protein that protects muscle fibers. Steroids (deflazacort, prednisone or vamorolone) and givinostat slow the loss of strength. Four exon-skipping drugs are approved in the U.S. for certain gene changes, but only under accelerated approval. Elevidys, a one-time gene therapy, makes a shortened dystrophin. Since November 14, 2025 it carries a boxed warning for serious liver injury and is limited to people 4 and older who can still walk. Our view: today's treatments slow Duchenne, they do not stop it, and several new drugs face FDA decisions in the next five months.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Care decisions belong with a Duchenne-experienced neuromuscular team.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your neuromuscular care team.
Could the benefit of a one-time dystrophin gene therapy fade over years, because the delivered gene copies are slowly lost from fibers that are still breaking down? Repeat muscle samples years after treatment would start to answer it, as would a test that tracks micro-dystrophin without a biopsy — a test that does not yet exist.
What would prove it wrong: if muscle samples taken years after treatment hold as much gene copy and micro-dystrophin as in the first months.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
In a survey of 186 caregivers (166 for Duchenne, 20 for Becker) from the PPMD Duchenne Registry, 86.1% were satisfied with multidisciplinary clinic care and 89% preferred seeing all providers at once. Families traveled an average of about 228 miles, and some raised concerns about travel, visit length and moving to adult care. A survey of opinions, not a treatment study.
In mouse models of Duchenne, CAR T cells aimed at uPAR, a marker on inflammatory and scar-forming cells in muscle, removed those cells and improved muscle regeneration, strength and breathing-muscle (diaphragm) function. It was tested only in mice, not in people.
In boys aged 4 to under 7, muscle function over 30 months on vamorolone (22 boys) did not differ significantly from matched boys on prednisone (32) or deflazacort (34). Height held steady on vamorolone but fell on the other steroids, and spine fractures were about half as common on vamorolone (12.8% of boys vs 25.9% and 28.6%). It was an open-label, non-randomized comparison with outside control data, and several authors work for the drug makers.
In 64 walking boys treated in EMBARK part 1, compared with 143 matched untreated boys from other studies (an outside control group, not a placebo group at year 3), the treated boys scored 4.39 points better on the North Star Ambulatory Assessment and rose from the floor 6.05 seconds faster at 3 years (nominal P values). The authors, who include Sarepta staff, report no new safety signals and no treatment-related deaths.
A single-dose CRISPR (hfCas12Max) therapy given in an AAV9 vector partly restored dystrophin in mice and showed editing in monkeys without dose-limiting toxicity. In the first-in-human trial (NCT06594094), muscle biopsies showed editing and some dystrophin. At the higher dose (1.0 × 10^14 vg/kg), one participant had a treatment-related fatal reaction with strong immune (complement) activation. The authors say this shows a narrow safe dose range for this kind of therapy.
Entrada reported its first group of 8 boys (6 on drug, 2 on placebo) given three doses of 5 mg/kg. Dystrophin rose by a very small 0.10% on average, safety was acceptable, and there was no benefit in movement or function yet. A higher dose group reports in the first half of 2027. These are company-reported results.
In EXPLORE44, 19 boys and men with exon 44 Duchenne got del-zota and 7 got placebo. Exon 44 skipping rose by 36.6% (5 mg/kg) and 43.4% (10 mg/kg) and dystrophin rose by about 25% in both groups, with no change on placebo. Most side effects were mild or moderate; two people on the lower dose stopped because of an allergic or infusion reaction. It was a small safety-focused trial and did not show a benefit in movement. The drug is under FDA review.
In 188 boys with Duchenne (median age 9.1), a computer model that combined muscle MRI fat measures with clinical scores predicted loss of walking with a C-index of 0.870 in a small test group (40 boys, 15 events). It outperformed a model using clinical scores alone (0.804). It may help plan care and trials; it is not a treatment and needs outside confirmation.
Capricor reported that in the open-label extension, people who switched from placebo to deramiocel lost 0.49 points of arm function in their first treated year versus 2.05 points on placebo. Of 106 randomized, 98 joined the extension. These are company-reported, descriptive results without statistical testing. The FDA decision date is still November 22, 2026.
NS Pharma reported that 6 people with exon 44 Duchenne given weekly infusions of brogidirsen for 5 years had no serious side effects. Motor function was kept or improved in those who stayed able to walk, and arm function held in all six. The release gave no numbers, and this is a very small, company-reported result.
Sarepta reported that 25 walking children treated at ages 8 to 12 did better on the North Star score (3.32 points) and on rising from the floor and walk/run speed over 2 years than 99 matched children who were not treated. This was a comparison with an outside group, not a randomized trial. Sarepta said no new safety signals were found.
The FDA accepted Avidity's application for accelerated approval of delpacibart zotadirsen (del-zota) for people whose gene change can be treated by skipping exon 44. A Phase 3 confirmatory trial, SAFARI44, has started. Acceptance is not approval.
After the July advisory vote, Capricor sent more HOPE-3 data, including 24-month follow-up. The FDA treated it as a major amendment and moved its decision date from August 22 to November 22, 2026.
The FDA approved a label update naming an authorized test to pick patients whose antibodies to the gene therapy's virus shell are low enough to treat.
Blood samples from a trial in boys aged 4 to under 7 showed that prednisone lowered 10 proteins linked to bone and cartilage growth. Vamorolone did not, and levels recovered after switching to vamorolone.
In 106 people aged 10 and older, the cell therapy slowed loss of arm function compared with placebo at 12 months (p=0.029). The same day, an FDA advisory committee voted 9–3 that the evidence does not show it works for Duchenne heart disease, citing changes to the analysis plan.
The FDA accepted Dyne's application for accelerated approval of z-rostudirsen for exon 51 skipping, with priority review and a decision date of January 21, 2027. The Phase 3 FORZETTO confirmatory trial is underway.
Even though ESSENCE missed its main goal, the FDA accepted Sarepta's request to convert casimersen and golodirsen to full approval. The decision date is February 28, 2027.
Regenxbio finished dosing its confirmatory study (63 people treated in total) and said it planned to file for accelerated approval in the third quarter of 2026. It reports that over 93% reached its microdystrophin goal at week 12.
All four boys treated at ages 4 to 7 were still walking at five years, and their North Star scores were well above matched untreated boys from other studies. No new safety signals were seen.
England's NICE recommended givinostat on the NHS for people aged 6 and older who can walk or stand, but not for those who can no longer walk.
Solid Biosciences reported strong microdystrophin levels, restored partner proteins and lower muscle-damage markers. The 40 children dosed so far used a steroid-only immune regimen. These are early, uncontrolled data from a company presentation.
In 122 walking boys aged 4 to 7, fordadistrogene movaparvovec did no better than placebo on the North Star score at one year. Serious side effects were more common, and Pfizer ended development.
Sarepta reported that the 52 treated boys stayed above their starting North Star score at year 3. The comparison was with 73 untreated boys from other studies (an external control), not a placebo group. Topline company data, not yet peer reviewed.
After two deaths from acute liver failure in people who could not walk, the FDA added a boxed warning, removed the non-walking group from the label and required a 200-person liver-safety study.
In 225 boys aged 6 to 13, the change in stair-climbing speed at 96 weeks was not significantly better than placebo. Dystrophin rose, and no new safety issues appeared.
Steroids are the base of care. Newer drugs and a gene therapy add to them for some people. Heart, lung and physical care protect the body as the disease moves on.
Daily steroids slow the loss of muscle strength. Long-term use can weaken bones and slow growth. Steroids must never be stopped suddenly.
A steroid-like drug. Studies suggest it works about as well as prednisone with less effect on bone and growth.
The first non-steroid pill for all gene types. In an 18-month trial in boys also taking steroids, it slowed the decline in four-stair-climb time compared with placebo. Watch for low platelets and high triglycerides.
Makes a shortened "micro-dystrophin". Its main Phase 3 trial (EMBARK) missed its main goal at one year, but the FDA gave full approval for walking patients in 2024 based on other measures. It can cause serious, sometimes fatal liver injury.
Weekly infusions for specific gene changes (exons 51, 53 or 45). They raise dystrophin a little. Benefit on strength has not yet been confirmed: ESSENCE and RACER53 missed their main goals.
Regular heart and breathing checks, heart medicines, breathing support, stretching and physical therapy are part of the international care guidelines.
| Treatment | For | What it does |
|---|---|---|
| Corticosteroids (deflazacort, prednisone, vamorolone) | Most people with Duchenne | Slows loss of strength. Needs bone, growth and weight monitoring. |
| Givinostat (Duvyzat) | Ages 6 and older | Slows muscle decline. Needs blood-count and lipid checks. |
| Delandistrogene moxeparvovec (Elevidys) | Ages 4+, still walking, eligible antibody test | One-time gene therapy. Weekly liver tests for 3 months after. |
| Exon-skipping drugs | Only certain gene changes | Raise dystrophin slightly. Accelerated approval only. |
| Heart, breathing & physical care | Everyone | Protects the heart and lungs and keeps joints flexible. |
No supplement replaces dystrophin or stops Duchenne. Daily care that protects muscles, bones, heart and lungs matters most. We rate each by the strength of evidence.
Care guidelines recommend regular stretching and supervised therapy to keep joints flexible.
PPMD advises keeping vaccines up to date and getting a flu shot every year. People on daily steroids should avoid live vaccines when possible.
A 2013 Cochrane review found short-term creatine raised muscle strength in muscular dystrophies. Ask the care team first.
The FDA warns these products are unapproved and have caused serious harm, including infections and blindness.
This can cause a life-threatening adrenal crisis. Steroids must be lowered slowly under medical care.
No supplement has been shown to restore dystrophin or stop Duchenne.
Be careful: people with Duchenne should never receive the anesthesia drug succinylcholine, which can cause dangerous potassium levels. Anyone on daily steroids needs stress-dose steroids for surgery or serious illness. Tell every emergency and surgical team about Duchenne and the steroids.
Centers recognized for expertise in this condition, and communities of people living with it.
A PPMD Certified Duchenne Care Center and a study site in Sarepta's Phase 3 EMBARK and ENVISION gene-therapy trials.
Certified by PPMD in June 2025 as a Duchenne Care Center and the first to receive PPMD's Clinical Research Designation.
A PPMD Certified Duchenne Care Center since 2023, and a study site in the EMBARK, ENVISION and HOPE-3 trials.
A PPMD Certified Duchenne Care Center and a study site in EMBARK and HOPE-3. A UC Davis physician is the first author of the published HOPE-3 trial.
A PPMD Certified Duchenne Care Center and a study site in the HOPE-3 trial of deramiocel.
A study site in the Phase 3 EMBARK and ENVISION gene-therapy trials.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
Duchenne affects the whole family, and other families understand. Most of these are free.
Local groups for families living with Duchenne and Becker, run through the largest U.S. Duchenne nonprofit.
Visit ↗Supports people with neuromuscular diseases, including Duchenne, with care-center networks, resources and events.
Visit ↗Funds research and shares plain-language updates on Duchenne treatments and trials.
Visit ↗A UK charity that funds research, pushes for access to new treatments and supports families.
Visit ↗Connects Duchenne and Becker patient organizations around the world.
Visit ↗Many private parent and caregiver groups exist. This link searches Facebook (a login is required).
Search Facebook ↗Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor. Protect your privacy, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
Steroids are used worldwide. Newer drugs differ a lot by country: Europe refused Elevidys and eteplirsen, and Japan approved Elevidys conditionally for younger children.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| Deflazacort (Emflaza)Steroid | Approved 2017 | — | — | — | — | — | — | — | — |
| Vamorolone (Agamree)Steroid-like | Approved 2023 | Approved 2023 | Approved 2024 | Approved 2025 | — | — | — | — | — |
| Givinostat (Duvyzat)Non-steroid pill | Approved 2024 | Conditional 2025 | Approved 2024 | — | — | — | — | — | — |
| Delandistrogene moxeparvovec (Elevidys)Gene therapy | Approved 2023 | Refused | — | — | Conditional 2025 | — | — | — | — |
| Eteplirsen (Exondys 51)Exon 51 skipping | Accelerated 2016 | Refused | — | — | — | — | — | — | — |
| Viltolarsen (Viltepso)Exon 53 skipping | Accelerated 2020 | — | — | — | Conditional 2020 | — | — | — | — |
| Golodirsen (Vyondys 53) & casimersen (Amondys 45)Exon 53 / 45 skipping | Accelerated 2019 / 2021 | — | — | — | — | — | — | — | — |
| Ataluren (Translarna)Nonsense mutations | — | Expired 2025 | — | — | — | — | — | — | — |
Japan approved Elevidys in May 2025 under a conditional, time-limited pathway for up to seven years. More data are needed for full approval. It is the first approval to include 3-year-olds.
A randomized, placebo-controlled Phase 3 trial of the SGT-003 gene therapy is recruiting in Sydney, Calgary, Vancouver and Toronto, with U.S. sites listed as not yet recruiting.
The confirmatory Phase 3 trial of del-zota is underway outside the United States while the FDA reviews it for accelerated approval.
Duchenne happens when a change in the DMD gene on the X chromosome stops the body from making dystrophin. Without it, muscle fibers are damaged each time they work.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
These organizations exist to help families affected by Duchenne pay for equipment, travel and care. Funds are limited and rules vary, so contact each one directly.
Financial help with travel to clinic appointments, equipment insurance doesn't cover, home changes, accessible vans and van changes, and urgent needs, plus help working through Medicaid waivers and SSI. No maximum is stated.
See the program ↗Helps with medical needs insurance usually doesn't cover. Past help has included an accessible van, service dogs, Hoyer lifts, home ramps and medical travel. No maximum or deadline is stated.
See the program ↗Adaptive equipment grants of up to $15,000 toward mobility and medical devices, vehicle changes and communication devices.
See the program ↗Grants toward durable medical equipment such as wheelchairs and lifts, subject to review and available funding.
See the program ↗Helps with copays, coinsurance, deductibles and other health costs for Duchenne treatment. The program was listed as open to new patients on October 6, 2026, but funds can run out.
Check fund status ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 3, 2026.
Not individually cited: that boys with Duchenne usually have one X chromosome and that Becker comes from the same gene are drawn from the MedlinePlus Genetics page; the step-by-step symptom ages come from the FDA's 2024 press release and MedlinePlus. Steroid side effects, the role of heart medicines and breathing support, and stretching and physical therapy reflect the 2018 international care considerations rather than a single trial. All "—" cells in the approvals table are unverified, and "Approved 2024" for givinostat in the UK rests on Duchenne UK and PMLiVE, which give December 2024 and January 2025 dates for the MHRA decision. The ESSENCE treatment difference is reported differently by different outlets (0.05 vs 0.06 steps per second), so we leave the number out. The SGT-003, RGX-202, z-rostudirsen and three-year EMBARK results rest on company announcements that are not yet peer reviewed. We could not confirm whether Regenxbio has filed its RGX-202 application yet, or find a decision date for del-zota. No Duchenne Reddit community could be confirmed, so none is listed. Expert care centers: certification status for Nationwide Children's, UC Davis and Cincinnati Children's comes from PPMD's live Certified Duchenne Care Center map. Great Ormond Street is listed for its trial-site role only. Financial help: checked October 6, 2026. Most of these pages block automated checks and were read with a headless browser. Laughing At My Nightmare and MDA cover more than Duchenne. Left out: Jett Foundation's Giving Fund (its site could not be opened), Michael's Cause (its home page says funds now go to research, which conflicts with its assistance form), and Muscular Dystrophy UK's Joseph Patrick Trust grants (paused).